Global Peanut Allergy Treatment Market Opportunities and Forecast 2023-2030

Peanut Allergy Treatment Market Overview

Peanut allergy is the most common allergy of childhood, which can cause several reactions including anaphylaxis. As per a new Northwestern Medicine study, peanut allergy affects at least 4.5 million adults in the U.S. The global Peanut Allergy Treatment market is projected to expand at a moderate rate during the forecast period. Factors such as the launch of new products in the market and increasing awareness about allergy are expected to drive the global Peanut Allergy Treatment market during the forecast period.

To date there were is no approved treatment available for the peanut allergy, however in January 2020, U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.

Moreover, the growing number of patient visits for the treatment of allergy to clinics and growth in research and development activities by manufacturers and healthcare organizations are expected to drive the global peanut allergy treatment market during the forecast period. In addition to this, growing health care expenditure and increasing demand for advanced drugs for peanut allergy are further driving the expansion of this market globally.

On the downside, Stringent regulation for the product approval and lack of awareness among patients and health care providers about the disease in developing countries is likely to hamper the global Peanut Allergy Treatment market during the forecast period.

Covid-19 Impact on Healthcare Biometrics Market:

In addition, the current Healthcare Biometrics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Healthcare Biometrics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Peanut Allergy Treatment Market Segment Overview

Based on Drug Type the market is segmented into Injectable Epinephrine and Antihistamines. Among these antihistamines, the segment holds the largest share of the market. It is found out that many patients suffering from very severe allergic reactions need an emergency injection of epinephrine and to visit the emergency room. However, there is a high rate of people suffering from mild allergies, thereby antihistamines are in more useful as compared to Epinephrine.

Based on the Route of Administration, the oral route of administration is more in use because of the less severe cases among the patients. Based on Distribution Channel Hospital Pharmacies segment holds the largest share of the market owing to safety and the patients should get medicines with label instructions and warnings under doctors’ supervision.

Peanut Allergy Treatment Market, By Drug Type

·       Epinephrine Injection (EpiPen, Twinject, AUVI-Q)
·       Antihistamines

Peanut Allergy Treatment Market, By Route of Administration

·       Oral
·       Injectable

Peanut Allergy Treatment Market, By Distribution Channel 

·       Retail Pharmacies
·       Hospital Pharmacies
·       Online Pharmacies
·       Drug Store

Peanut Allergy Treatment Market Regional Overview

Region-wise, North America dominated the global Peanut Allergy Treatment market and is expected to continue its dominance during the forecast period. This dominance is mainly due to the US having a large population of a potential patients. Moreover, factors such as rising awareness among people about allergy, and high health care expenditure propels the growth of the market in North America. similarly, Europe is also expected to account for a significant share of the global market owing to well-established health care infrastructure.

Additionally, the Asia Pacific is expected to register the fastest growth during the forecast period. Factors such as development in the health care infrastructure, rising awareness about health, a surge in investment in pharmaceuticals and biotechnology sectors, and increasing incidence of allergy in countries such as Australia are expected to escalate the growth of the Peanut Allergy Treatment market in Asia Pacific region. In Australia, there is a particularly high presence of peanut allergies with one in 200 adults, and almost three in every 100 children affected.

Peanut Allergy Treatment Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Peanut Allergy Treatment Market, Key Players

·       Mylan Inc.
·       Sanofi SA, Pfizer Inc.
·       kaleo, Inc.
·       Teva Pharmaceutical Industries Ltd.
·       Johnson & Johnson Inc.
·       DBV Technologies
·       Aimmune Therapeutics
·       Prota Therapeutics Pty Ltd.